- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 75438-57-2] Moxonidine
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B0374 |
| Brand: | MCE |
| CAS: | 75438-57-2 |
Overview
| MDL | MFCD00865794 |
|---|---|
| Molecular Weight | 241.68 |
| Molecular Formula | C9H12ClN5O |
| SMILES | CC1=NC(OC)=C(NC2=NCCN2)C(Cl)=N1 |
Summary
Moxonidine(BDF5895) is a selective agonist at the imidazoline receptor subtype 1, used as antihypertensive agent. Target: I1-R Moxonidine is a centrally acting antihypertensive agent. Mixed Nischarin (I1 imidazoline receptor) and α2-AR (adrenergic) agonist; displays 40-fold higher affinity for I1 receptors versus α2-adrenoceptors. Moxonidine reduced stimulated NE overflow (log EC50: -6.15 +/- 0.14). AGN192403, a selective ligand at I1-R, had no influence on the dose-response curve of moxonidine (log EC50: -6.01 +/- 0.25) [1]. The hypotensive and bradycardic actions of moxonidine but not clonidine are mediated through imidazoline receptors and are dependent on intact noradrenergic pathways within the RVLM. Furthermore, the noradrenergic innervation may be associated with a 42 kDa imidazoline receptor protein [2].
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04329806 | Italo Biaggioni|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University Medical Center |
Obesity-Associated Insulin Resistance
|
February 23, 2021 | Phase 1 |
| NCT04023565 | Sergey V. Nedogoda|Volgograd State Medical University |
Arterial Hypertension|Metabolic Syndrome
|
March 11, 2019 | Phase 4 |
| NCT01504321 | Baker Heart and Diabetes Institute |
Polycystic Ovary Syndrome
|
May 2012 | Phase 4 |
| NCT01791699 | Spyridon Deftereos|G.Gennimatas General Hospital |
Atrial Fibrillation
|
August 2012 | Phase 4 |
| NCT01094769 | Baker Heart and Diabetes Institute |
Diabetic Nephropathies
|
April 2011 | Phase 4 |
| NCT05147753 | Aristotle University Of Thessaloniki |
Obesity|Hypertension
|
January 11, 2010 | Phase 4 |
| NCT04050410 | Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI) |
Postural Tachycardia Syndrome
|
August 27, 2019 | Early Phase 1 |
| NCT01360710 | Baker Heart and Diabetes Institute |
Abdominal Obesity|Hypertension
|
January 2012 | Phase 4 |
| NCT00244504 | University Hospital, Basel, Switzerland |
Cardiac Disease|Vascular Surgery
|
November 2002 | Phase 3 |
| NCT01567124 | Baker Heart and Diabetes Institute|The Alfred|Monash Medical Centre|Ballarat Health Services |
Schizophrenia
|
May 2012 | Phase 4 |
| NCT01180231 | Baker Heart and Diabetes Institute |
Obesity|Overweight
|
September 2010 | Phase 4 |
| NCT00160277 | Solvay Pharmaceuticals |
Hypertension
|
July 2005 | Phase 3 |
| NCT00518479 | University of Leeds|The Leeds Teaching Hospitals NHS Trust |
Hypertension|Left Ventricular Hypertrophy
|
September 2003 | Not Applicable |
| NCT02355821 | National Research Center for Preventive Medicine|National Medical Research Center for Therapy and Preventive Medicine |
Osteopenia|Arterial Hypertension
|
April 2015 | Not Applicable |
| NCT01138423 | UMC Utrecht|Novartis Pharmaceuticals |
Hypertension|Abdominal Obesity|Metabolic Syndrome
|
August 2010 | Phase 4 |
| NCT04474899 | Royal Perth Hospital|The University of Western Australia |
Obesity|Hypertension
|
June 24, 2015 | Phase 4 |
| NCT04479813 | Royal Perth Hospital |
Central Sympathetic Nervous System Diseases
|
July 8, 2015 | Phase 4 |
| NCT05312892 | Vanderbilt University Medical Center |
Obesity|Hypertension
|
May 20, 2022 | Phase 1|Phase 2 |
| NCT04140721 | Vanderbilt University Medical Center|National Heart, Lung, and Blood Institute (NHLBI) |
Postural Tachycardia Syndrome
|
August 31, 2021 | Early Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 20 mg/mL ( 82.75 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.1377 mL | 20.6885 mL | 41.3770 mL |
| 5 mM | 0.8275 mL | 4.1377 mL | 8.2754 mL |
| 10 mM | 0.4138 mL | 2.0689 mL | 4.1377 mL |
References
- [1] Schafer, U., et al., Presynaptic effects of moxonidine in isolated buffer perfused rat hearts: role of imidazoline-1 receptors and alpha2-adrenoceptors. J Pharmacol Exp Ther, 2002. 303(3): p. 1163-70.
- [2] Chan, C.K., et al., Imidazoline receptors associated with noradrenergic terminals in the rostral ventrolateral medulla mediate the hypotensive responses of moxonidine but not clonidine. Neuroscience, 2005. 132(4): p. 991-1007.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.